Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data

Aman U. Buzdar, Jack Cuzick, Carlos Arteaga, Stephen Johnston, Kathleen Pritchard, Eric Winer, Steven Come, James Ingle, Mitch Dowsett

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after ≥2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number3 II
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
Aromatase Inhibitors
exemestane
letrozole
Safety
Therapeutics
Disease-Free Survival
anastrozole
Recurrence
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Buzdar, A. U., Cuzick, J., Arteaga, C., Johnston, S., Pritchard, K., Winer, E., ... Dowsett, M. (2006). Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clinical Cancer Research, 12(3 II). https://doi.org/10.1158/1078-0432.CCR-05-2458

Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer : Emerging data. / Buzdar, Aman U.; Cuzick, Jack; Arteaga, Carlos; Johnston, Stephen; Pritchard, Kathleen; Winer, Eric; Come, Steven; Ingle, James; Dowsett, Mitch.

In: Clinical Cancer Research, Vol. 12, No. 3 II, 01.02.2006.

Research output: Contribution to journalArticle

Buzdar, AU, Cuzick, J, Arteaga, C, Johnston, S, Pritchard, K, Winer, E, Come, S, Ingle, J & Dowsett, M 2006, 'Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data', Clinical Cancer Research, vol. 12, no. 3 II. https://doi.org/10.1158/1078-0432.CCR-05-2458
Buzdar, Aman U. ; Cuzick, Jack ; Arteaga, Carlos ; Johnston, Stephen ; Pritchard, Kathleen ; Winer, Eric ; Come, Steven ; Ingle, James ; Dowsett, Mitch. / Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer : Emerging data. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 3 II.
@article{78b76b17c1394990bd516011308880a1,
title = "Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data",
abstract = "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after ≥2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking.",
author = "Buzdar, {Aman U.} and Jack Cuzick and Carlos Arteaga and Stephen Johnston and Kathleen Pritchard and Eric Winer and Steven Come and James Ingle and Mitch Dowsett",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-05-2458",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3 II",

}

TY - JOUR

T1 - Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer

T2 - Emerging data

AU - Buzdar, Aman U.

AU - Cuzick, Jack

AU - Arteaga, Carlos

AU - Johnston, Stephen

AU - Pritchard, Kathleen

AU - Winer, Eric

AU - Come, Steven

AU - Ingle, James

AU - Dowsett, Mitch

PY - 2006/2/1

Y1 - 2006/2/1

N2 - The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after ≥2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking.

AB - The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women. Analyses at 33 and 47 months median follow-up showed that anastrozole significantly prolonged disease-free survival and time to recurrence and reduced the incidence of contralateral breast cancer compared with tamoxifen. Results of the completed treatment analysis at 68 months median follow-up confirmed the earlier findings, showing that the absolute difference in disease-free survival continued to increase beyond completion of treatment. Mature safety data from the ATAC trial show that, overall, anastrozole has a favorable safety profile compared with tamoxifen. In the absence of current data on further follow-up or the outcome of trials investigating proactive sequencing of endocrine therapies, we present a model based on several trials, including ATAC. This model suggests that using an aromatase inhibitor as initial adjuvant therapy is a better option than switching to an aromatase inhibitor after ≥2 years of tamoxifen. The relative toxicities of the three approved third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, are discussed. These data suggest that long-term safety profiles may differ between aromatase inhibitors, although comprehensive comparative data for letrozole and exemestane versus tamoxifen are lacking.

UR - http://www.scopus.com/inward/record.url?scp=32944458406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944458406&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2458

DO - 10.1158/1078-0432.CCR-05-2458

M3 - Article

C2 - 16467122

AN - SCOPUS:32944458406

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3 II

ER -